<DOC>
	<DOCNO>NCT02631096</DOCNO>
	<brief_summary>The study phase 2a , single blind , randomize , placebo control , study evaluate safety , anti-viral activity , pharmacokinetics ( PK ) follow multiple dos intravenous ARB-001467</brief_summary>
	<brief_title>Study ARB-001467 Subjects With Chronic HBV Infection Receiving Nucleos ( ) Ide Analogue Therapy</brief_title>
	<detailed_description>Approximately 24 subject enrol three cohort : two cohort HBeAg-negative subject one cohort HBeAg-positive subject . All subject non-cirrhotic , chronic hepatitis B virus ( HBV ) infection , receive nucleos ( ) ide-analogue ( NA ) therapy entecavir tenofovir least 12 month .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Key Documented chronic HBV infection ≥12 month prior Screening Visit . Quantitative HBsAg ≥1000 IU/mL Screening Visit . Subjects currently receive entecavir tenofovir ≥12 month HBV DNA undetectable . Key Known coinfection HIV , hepatitis C virus , hepatitis D virus . Receiving plan receive systemic immunosuppressive medication study ≤2 month prior first dose study treatment . Receiving plan receive interferon study ≤12 month prior first dose study treatment . Significant immunosuppression , limited immunodeficiency condition common variable hypogammaglobulinemia . Clinical diagnosis substance abuse alcohol , narcotic , cocaine ≤12 month prior Screening Visit . Any known preexisting medical psychiatric condition could interfere subject 's ability provide inform consent participate study conduct , may confound study finding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>